IMPRESS trial data on continuing tyrosine kinase inhibitor therapy after resistance development in lung cancer reported
This item is under embargo and is only visible to journalists
Please login here
Regions: Europe, Spain, Switzerland, Asia, China
Keywords: Health, Medical, Public Dialogue - health
The item has been withdrawn. If you are a journalists please contact the person that posted the item with any questions.